BCL2L13 and myeloid sarcoma: It decreases BCL2L13 expression in non-MS PBMCs and monocytes, and increases BCL2L13 expression in MS PBMCs and monocytes, and its relevant microRNAs are also expressed in monocytes [6, 38–40] (Additional file 1: Table S9, Additional file 1: Table S11).